3347:HKEXHangzhou Tigermed Consulting Co., Ltd. Class H Analysis

Hangzhou Tigermed Consulting delivers ~HK$6.6 bn of revenue with modest 3.9% growth and thin profit margins (≈9% net), while maintaining a solid cash position of HK$1.7 bn that just about offsets its HK$1.75 bn debt load. However, the stock trades at a trailing P/E of ~51× versus an industry average of ~26× and a DCF‑derived fair value of only HK$11.8, suggesting the market is pricing in far higher growth expectations than current fundamentals support.
Technical indicators are mixed: the 20‑day SMA (≈45.8) sits below both the 50‑day (≈48.9) and 200‑day (≈45.5) averages, the MACD is bearish, and RSI is near 40, indicating limited upside momentum. Volume is rising, but high 30‑day volatility (~61%) and a low beta imply price swings are driven more by company‑specific news than market moves. The dividend yield is modest (~0.8%) with a payout ratio around 42%, which appears sustainable given the cash flow generation.